Finance

Lists
Q2 2026 earnings • released • EPS beat +341.36% • Revenue miss -44.48%
See results
MGNX:NASDAQ
MacroGenics Inc
$4.13
-2.13%
(-0.090) 1D
Aug 17, 11:35:03 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MGNX...
Open
$4.21
High
$4.30
Low
$4.06
Mkt. cap
262.86M
Avg. vol.
752.45K
Volume
143.16K
52-wk high
$5.08
52-wk low
$1.30
EPS
-$1.11
Beta
1.20
Shares outstanding
63.56M
No. of employees
293
Open
$4.21
High
$4.30
Low
$4.06
Mkt. cap
262.86M
Avg. vol.
752.45K
Volume
143.16K
52-wk high
$5.08
52-wk low
$1.30
EPS
-$1.11
Beta
1.20
Shares outstanding
63.56M
No. of employees
293
News stories
From web sources and news partners
About MacroGenics Inc
CEO-
Employees293
Founded2000
HeadquartersRockville, Maryland, United States
SectorBiotechnology
Websitemacrogenics.com
Analyst ratings
Based on 4 analysts giving stock ratings to MGNX in the past 3 months
Buy
Buy
2
Hold
2
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for MGNX in the last 3 months.
Highest
Current $4.13
$11.00 (+166.34%)
Average
$7.00 (+69.49%)
Lowest
$4.00 (-3.15%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mayank Mamtani
B. Riley Securities
Buy
Maintained
$11.00
+166.3%
08/17/2026
Stephen Willey
Stifel Nicolaus
Hold
Reiterated
$4.00
-3.1%
08/14/2026
Etzer Darout
Barclays
Buy
Maintained
$6.00
+45.3%
08/14/2026
Tara Bancroft
TD Cowen
Hold
Maintained
-
-
08/13/2026
Robert Burns
H.C. Wainwright
Hold
Reiterated
-
-
05/07/2026
Last report
Aug 13, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$1.14 / $0.26
+341.36%beat
Revenue / Est. (USD)
32.83M / 59.14M
-44.48%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
72.84M
41.23M
6.72M
32.83M
Cost of goods sold
44.30M
44.09M
34.97M
38.78M
Cost of revenue
44.30M
44.09M
34.97M
38.78M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.90M
9.24M
9.71M
7.90M
Operating expense
9.90M
9.24M
9.71M
7.90M
Total operating expenses
54.20M
53.32M
44.68M
46.68M
Operating income
18.64M
-12.10M
-37.96M
-13.85M
Other non operating income
-
-
-
-
EBT including unusual items
16.82M
-14.93M
-41.30M
-69.64M
EBT excluding unusual items
16.82M
-14.93M
-41.30M
-16.88M
Income tax expense
-
-777.00K
-
-
Effective tax rate
-
5.20%
-
-
Other operating expenses
-
-
-
-
Net income
16.82M
-14.16M
-36.77M
19.52M
Net profit margin
23.09%
-34.33%
-547.15%
59.44%
Earnings per share
0.27
-0.22
-0.58
1.14
Interest and investment income
1.53M
1.44M
1.55M
1.37M
Interest expense
-3.34M
-4.27M
-4.89M
-4.40M
Net interest expenses
-1.81M
-2.84M
-3.34M
-3.03M
Depreciation and amortization charges
-
-
-
-
EBITDA
20.42M
-10.39M
-36.28M
-13.14M
Gain or loss from assets sale
-
-10.00K
-
-94.49M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps